Quantum Genomics Société Anonyme announces that efficacy results for firibastat in its phase III study FRESH, are non-significant versus placebo. These results will be presented in detail at the AHA congress.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.1198 EUR | -7.28% | +7.73% | +13.02% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+13.02% | 4.81M | |
+1.77% | 42.75B | |
+47.70% | 41.61B | |
+12.24% | 41.34B | |
-8.83% | 26.59B | |
+7.44% | 25.49B | |
-23.01% | 18.12B | |
+30.56% | 12.24B | |
-1.82% | 11.76B | |
+8.35% | 11B |
- Stock Market
- Equities
- ALQGC Stock
- News Quantum Genomics
- Quantum Genomics Announces Lack of Significant Efficacy for Firibastat in Their Phase III Study, Fresh and Is Redirecting to New Developments